Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas

Detalhes bibliográficos
Autor(a) principal: Silva, S. L
Data de Publicação: 2004
Outros Autores: Silva, S. F. R, Farias, I. N, Mota, R. S, Carvalho, Reinaldo de Amorim, Moraes, M. O, Moraes, M. E, Campos, H. de Holanda
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
Texto Completo: https://patua.iec.gov.br/handle/iec/449
Resumo: Purpose. To investigate the effect of rapamycin (Rapa) on growth or regression of Walker tumor used alone or in combination with CsA and MMF. Methods and results. Wistar rats received water (control) or Rapa or CsA 1 day before and daily after tumor inoculation. On day 10, tumor volume (TV) was smaller among Rapa (6.8 2.7 cm3 ) versus control (14.9 4.2 cm3 , P .001) or CsA (13.9 3.0 cm3 , P .0001) treatment groups. Tumor growth was greatly inhibited (TI) by Rapa (49.3%). Tumor weight (TW) was significantly (P .001) lower in Rapa (3.7 1.2 g) versus CsA (8.8 2.1 g) or control (7.3 2.0 g) animals. An additional set of rats received water or Rapa or CsA Rapa, or MMF Rapa 1 day before tumor inoculation. On day 10, TV and TW were lower among Rapa (3.8 1.5 cm3 ) and Rapa CsA (3.1 1.2 cm3 ) and Rapa MMF (4.6 2.7 cm3 ) groups compared with controls (10.9 3.8 cm3 , P .0001). TI was 52.1% in Rapa, 68.5% in Rapa CsA, and 63% in Rapa MMF. A further set of rats received either water or Rapa on the day 4 after tumor inoculation. On day 10, tumor growth and TW among the Rapa and control groups were similar. Conclusion. Rapamycin greatly inhibited tumor growth when used alone or with CsA or MMF, but did not produce an effect on a well-established Walker sarcoma.
id IEC-2_9fc1a7b75b9e790ca7d6cf3f01860ca8
oai_identifier_str oai:patua.iec.gov.br:iec/449
network_acronym_str IEC-2
network_name_str Repositório Digital do Instituto Evandro Chagas (Patuá)
repository_id_str
spelling Silva, S. LSilva, S. F. RFarias, I. NMota, R. SCarvalho, Reinaldo de AmorimMoraes, M. OMoraes, M. ECampos, H. de Holanda2016-01-26T11:28:08Z2016-01-26T11:28:08Z2004SILVA, S. L. et al. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas. Transplantation Proceedings, v. 36, n. 4, p. 934-937, 2004.0041-1345https://patua.iec.gov.br/handle/iec/44910.1016/j.transproceed.2004.03.126Purpose. To investigate the effect of rapamycin (Rapa) on growth or regression of Walker tumor used alone or in combination with CsA and MMF. Methods and results. Wistar rats received water (control) or Rapa or CsA 1 day before and daily after tumor inoculation. On day 10, tumor volume (TV) was smaller among Rapa (6.8 2.7 cm3 ) versus control (14.9 4.2 cm3 , P .001) or CsA (13.9 3.0 cm3 , P .0001) treatment groups. Tumor growth was greatly inhibited (TI) by Rapa (49.3%). Tumor weight (TW) was significantly (P .001) lower in Rapa (3.7 1.2 g) versus CsA (8.8 2.1 g) or control (7.3 2.0 g) animals. An additional set of rats received water or Rapa or CsA Rapa, or MMF Rapa 1 day before tumor inoculation. On day 10, TV and TW were lower among Rapa (3.8 1.5 cm3 ) and Rapa CsA (3.1 1.2 cm3 ) and Rapa MMF (4.6 2.7 cm3 ) groups compared with controls (10.9 3.8 cm3 , P .0001). TI was 52.1% in Rapa, 68.5% in Rapa CsA, and 63% in Rapa MMF. A further set of rats received either water or Rapa on the day 4 after tumor inoculation. On day 10, tumor growth and TW among the Rapa and control groups were similar. Conclusion. Rapamycin greatly inhibited tumor growth when used alone or with CsA or MMF, but did not produce an effect on a well-established Walker sarcoma.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.Fortaleza University. Fortaleza, CE, Brasil.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.Federal University of Ceará. Faculty of Medicine. Renal Transplant Unit. Fortaleza, CE, Brasil.application/pdfengElsevierRapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomasinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleSirolimo / uso terapêuticoSarcomaCarcinoma 256 de WalkerRatos WistarInoculação de NeoplasiaCarcinoma 256 de Walker / induzido quimicamenteinfo:eu-repo/semantics/openAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECORIGINALRapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas .pdfapplication/pdf164321https://patua.iec.gov.br/bitstreams/084dcfa4-39ee-4f1e-8d62-fd8f49277270/download22a5c4f9c61b9d8cf725e1a3ec09afeaMD51TEXTfile_1.pdf.txtfile_1.pdf.txtExtracted texttext/plain13934https://patua.iec.gov.br/bitstreams/47feb486-01eb-4c77-a20b-710f8b57bc58/downloadaca845a3586af0f829febf5eeffd2a6aMD52Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas .pdf.txtRapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas .pdf.txtExtracted texttext/plain14783https://patua.iec.gov.br/bitstreams/f9f1673e-2cc3-4ddd-8115-93f23ec968d6/downloadff15ff82acbd90229dc9ca2283ac416cMD57THUMBNAILfile_1.pdf.jpgfile_1.pdf.jpgIM Thumbnailimage/jpeg5011https://patua.iec.gov.br/bitstreams/747ae549-d82f-4122-b123-c87af6bef56b/downloadfc201484bdebd8171bd3e3f493bcdbd8MD53Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas .pdf.jpgRapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas .pdf.jpgGenerated Thumbnailimage/jpeg5873https://patua.iec.gov.br/bitstreams/e3e7eeae-3f9e-438b-92ee-7334f78c2559/downloade5d26b831ffe2e26659a987ad796461fMD58LICENSElicense.txtlicense.txttext/plain; charset=utf-82182https://patua.iec.gov.br/bitstreams/40819895-cdef-4492-afbf-494a0c00507b/download11832eea31b16df8613079d742d61793MD56iec/4492022-10-20 22:40:07.973oai:patua.iec.gov.br:iec/449https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2022-10-20T22:40:07Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)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
dc.title.pt_BR.fl_str_mv Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
title Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
spellingShingle Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
Silva, S. L
Sirolimo / uso terapêutico
Sarcoma
Carcinoma 256 de Walker
Ratos Wistar
Inoculação de Neoplasia
Carcinoma 256 de Walker / induzido quimicamente
title_short Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
title_full Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
title_fullStr Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
title_full_unstemmed Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
title_sort Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
author Silva, S. L
author_facet Silva, S. L
Silva, S. F. R
Farias, I. N
Mota, R. S
Carvalho, Reinaldo de Amorim
Moraes, M. O
Moraes, M. E
Campos, H. de Holanda
author_role author
author2 Silva, S. F. R
Farias, I. N
Mota, R. S
Carvalho, Reinaldo de Amorim
Moraes, M. O
Moraes, M. E
Campos, H. de Holanda
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, S. L
Silva, S. F. R
Farias, I. N
Mota, R. S
Carvalho, Reinaldo de Amorim
Moraes, M. O
Moraes, M. E
Campos, H. de Holanda
dc.subject.decsPrimary.pt_BR.fl_str_mv Sirolimo / uso terapêutico
Sarcoma
Carcinoma 256 de Walker
Ratos Wistar
Inoculação de Neoplasia
Carcinoma 256 de Walker / induzido quimicamente
topic Sirolimo / uso terapêutico
Sarcoma
Carcinoma 256 de Walker
Ratos Wistar
Inoculação de Neoplasia
Carcinoma 256 de Walker / induzido quimicamente
description Purpose. To investigate the effect of rapamycin (Rapa) on growth or regression of Walker tumor used alone or in combination with CsA and MMF. Methods and results. Wistar rats received water (control) or Rapa or CsA 1 day before and daily after tumor inoculation. On day 10, tumor volume (TV) was smaller among Rapa (6.8 2.7 cm3 ) versus control (14.9 4.2 cm3 , P .001) or CsA (13.9 3.0 cm3 , P .0001) treatment groups. Tumor growth was greatly inhibited (TI) by Rapa (49.3%). Tumor weight (TW) was significantly (P .001) lower in Rapa (3.7 1.2 g) versus CsA (8.8 2.1 g) or control (7.3 2.0 g) animals. An additional set of rats received water or Rapa or CsA Rapa, or MMF Rapa 1 day before tumor inoculation. On day 10, TV and TW were lower among Rapa (3.8 1.5 cm3 ) and Rapa CsA (3.1 1.2 cm3 ) and Rapa MMF (4.6 2.7 cm3 ) groups compared with controls (10.9 3.8 cm3 , P .0001). TI was 52.1% in Rapa, 68.5% in Rapa CsA, and 63% in Rapa MMF. A further set of rats received either water or Rapa on the day 4 after tumor inoculation. On day 10, tumor growth and TW among the Rapa and control groups were similar. Conclusion. Rapamycin greatly inhibited tumor growth when used alone or with CsA or MMF, but did not produce an effect on a well-established Walker sarcoma.
publishDate 2004
dc.date.issued.fl_str_mv 2004
dc.date.accessioned.fl_str_mv 2016-01-26T11:28:08Z
dc.date.available.fl_str_mv 2016-01-26T11:28:08Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv SILVA, S. L. et al. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas. Transplantation Proceedings, v. 36, n. 4, p. 934-937, 2004.
dc.identifier.uri.fl_str_mv https://patua.iec.gov.br/handle/iec/449
dc.identifier.issn.-.fl_str_mv 0041-1345
dc.identifier.doi.-.fl_str_mv 10.1016/j.transproceed.2004.03.126
identifier_str_mv SILVA, S. L. et al. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas. Transplantation Proceedings, v. 36, n. 4, p. 934-937, 2004.
0041-1345
10.1016/j.transproceed.2004.03.126
url https://patua.iec.gov.br/handle/iec/449
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Digital do Instituto Evandro Chagas (Patuá)
instname:Instituto Evandro Chagas (IEC)
instacron:IEC
instname_str Instituto Evandro Chagas (IEC)
instacron_str IEC
institution IEC
reponame_str Repositório Digital do Instituto Evandro Chagas (Patuá)
collection Repositório Digital do Instituto Evandro Chagas (Patuá)
bitstream.url.fl_str_mv https://patua.iec.gov.br/bitstreams/084dcfa4-39ee-4f1e-8d62-fd8f49277270/download
https://patua.iec.gov.br/bitstreams/47feb486-01eb-4c77-a20b-710f8b57bc58/download
https://patua.iec.gov.br/bitstreams/f9f1673e-2cc3-4ddd-8115-93f23ec968d6/download
https://patua.iec.gov.br/bitstreams/747ae549-d82f-4122-b123-c87af6bef56b/download
https://patua.iec.gov.br/bitstreams/e3e7eeae-3f9e-438b-92ee-7334f78c2559/download
https://patua.iec.gov.br/bitstreams/40819895-cdef-4492-afbf-494a0c00507b/download
bitstream.checksum.fl_str_mv 22a5c4f9c61b9d8cf725e1a3ec09afea
aca845a3586af0f829febf5eeffd2a6a
ff15ff82acbd90229dc9ca2283ac416c
fc201484bdebd8171bd3e3f493bcdbd8
e5d26b831ffe2e26659a987ad796461f
11832eea31b16df8613079d742d61793
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)
repository.mail.fl_str_mv clariceneta@iec.gov.br || Biblioteca@iec.gov.br
_version_ 1809190049133101056